ReviewBMC medical genomics2025
PET/CT and exome sequencing in late onset multiple acyl-CoA dehydrogenase deficiency: a case series and literature review.
Review in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple acyl-CoA dehydrogenase deficiency (MADD) is a rare autosomal recessive disorder. Riboflavin-responsive MADD (RR-MADD) represents a treatable subtype, though its molecular mechanisms are incompletely characterized. CASE PRESENTATION: Two patients presented to department of Rheumatology, the 3rd Affiliated Hospital of Sun Yet-sen University with progressive proximal muscle weakness. A 2-fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan revealed marked metabolic hyperactivity in cervical and paraspinal muscles. Histopathology confirmed lipid storage myopathy, and exome sequencing (ES) identified electron transfer flavoprotein dehydrogenase gene (ETFDH) mutations. Both patients harbored the common variant NM_004453.4:c.250G > A (p.Ala84Thr). Case 1 exhibited homozygosity for this variant and potential XYY syndrome, while Case 2 carried a compound heterozygous mutation including a novel frameshift variant, NM_004453.4: c.265_266del (p. Gln89Valfs*6), and concurrent SLC25A13 mutation linked to adult-onset citrullinemia type II. Riboflavin supplementation achieved complete biochemical remission in both cases. Retrospective analysis for previous reports of homozygous single-locus missense ETFDH gene mutations revealed that patients with mutations in the flavin adenine dinucleotide binding domain (FAD) or the iron-sulfur cluster domain (Fe-S) exhibited a better response to riboflavin and better prognosis. DISCUSSION: 18F-FDG PET/CT is a promising tool for evaluating myopathic involvement in MADD. ES enables rapid and comprehensive diagnosis of MADD and detection of coexisting genetic disorders. The prognosis is related to mutation forms, mutation pathogenicity, and the located structural domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.